- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04471116
Influence of Probiotics on the Vaginal Microbiota
Influence of OMNi-BiOTiC® FLORA Plus+ on the Vaginal Microbiome of Patients Suffering From Infertility
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Infertility is a global phenomenon affecting around 186 millions of people worldwide. Many circumstances have been identified to cause infertile conditions, with age being one of the most limiting factors. However, in recent years the microbiome has gained importance in the treatment of infertility and is considered as another important player to improve success rate of reproductive medicine treatments like in-vitro-fertilization (IVF).
Within the female reproductive tract the dominance of Lactobacilli is associated with a healthy vaginal microbial community in healthy reproductive-aged women. Since the microbiome has gained so much importance, its influence in IVF treatments is still controversially discussed. While some studies suggest a negative influence of vaginal dysbiosis on pregnancy rates a current meta-analysis showed no association between abnormal vaginal flora and conception rates following IVF treatment. One therapeutic approach is the administration of beneficial microorganisms (probiotics), mainly Lactobacillus species. The supplementation of exogenous lactobacilli strains has been suggested as cure for a dysbiotic vaginal flora to re-establish healthy conditions and improving female fertility health.
Hence, in the present study we wanted to investigate the impact of 4 probiotic strains (Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116) on the relative abundance of vaginal microbiata species in women suffering from infertility.
80 infertile women suffering from infertility were included in the study within fertility treatment. 40 patients with IVF / ICSI were examined (20 with OMNi-BiOTiC® FLORA plus +, 20 as a control) and 40 patients with IUI / VZO (20 with OMNi-BiOTiC® FLORA plus +, 20 as a control). The control patients were selected from the routine patient collective of the Kinderwunsch Institut Schenk GmbH and receive no treatment with probiotics or placebo. Patients in the therapy group took 1 sachet of OMNi-BiOTiC® FLORA plus + (= 2 g) dissolved in 1/8 l of water once a day. Patients in the control group received no additional medication for routine treatment. Patients were randomized after inclusion in the study (block randomization).
On day 20 in the pre-cycle of hormonal stimulation, a vaginal smear sample was taken from the patient. The investigator introduced a sterile swab (eSwabTM, Copan Diagnostics Inc., USA), and took material from the mucosal surface. The eSwab was transferred to a sterile Falcon tube, stored at -72 ° C and then handed over to the company biovis Diagnostik MVZ GmbH (Germany) for 16s rRNA gene analysis. On day 20 in the stimulated cycle or subsequent cycle of the fertility treatment, another vaginal smear sample was taken and also stored in a sterile Falcon tube at -72 ° C.
The microbiota was determined using 16s rRNA gene analysis. The bacterial genomic DNA was isolated from the samples and the region V3-V4 was sequenced (Nextera XT, DNA Library Preparation Kit; Illumina MiSeq, Illumina, The Netherlands).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Styria
-
Dobl, Styria, Austria, 8143
- Das Kinderwunsch Institut Schenk GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with primary or secondary infertility
- age between 18 and 40
- signed informed consent
- BMI between 19 and 29.9
Exclusion Criteria:
- Patients with severe, acute and / or chronic diseases
- obesity
- hirsutism
- current intake of antibiotics
- State after hysterectomy
- Simultaneous use of other probiotics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Therapy group
Patients in the therapy group took 1 sachet of OMNi-BiOTiC® FLORA plus + (= 2 g) dissolved in 1/8 l of water once a day
|
OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis).
The product combines probiotic bacterial strains with a special fiber mixture.
The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
|
No Intervention: Control group
Patients in the control group received no additional medication.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
vaginal microbiome
Time Frame: 1 month
|
The microbiota was determined using 16s rRNA gene analysis.
The bacterial genomic DNA was isolated from the samples and the region V3-V4 was sequenced
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Schenk, MD, Kinderwunsch Institut GmbH
Publications and helpful links
General Publications
- Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update. 2015 Jul-Aug;21(4):411-26. doi: 10.1093/humupd/dmv016. Epub 2015 Mar 22.
- Moreno I, Codoner FM, Vilella F, Valbuena D, Martinez-Blanch JF, Jimenez-Almazan J, Alonso R, Alama P, Remohi J, Pellicer A, Ramon D, Simon C. Evidence that the endometrial microbiota has an effect on implantation success or failure. Am J Obstet Gynecol. 2016 Dec;215(6):684-703. doi: 10.1016/j.ajog.2016.09.075. Epub 2016 Oct 4.
- Miles SM, Hardy BL, Merrell DS. Investigation of the microbiota of the reproductive tract in women undergoing a total hysterectomy and bilateral salpingo-oopherectomy. Fertil Steril. 2017 Mar;107(3):813-820.e1. doi: 10.1016/j.fertnstert.2016.11.028. Epub 2017 Jan 6.
- Haahr T, Jensen JS, Thomsen L, Duus L, Rygaard K, Humaidan P. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.
- van Oostrum N, De Sutter P, Meys J, Verstraelen H. Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis. Hum Reprod. 2013 Jul;28(7):1809-15. doi: 10.1093/humrep/det096. Epub 2013 Mar 29.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FRED002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginal Microbiome
-
University Hospital, AntwerpRecruitingSkin Microbiome | Vaginal Microbiome | Saliva MicrobiomeBelgium
-
Hillel Yaffe Medical CenterUnknown
-
Peking Union Medical College HospitalNot yet recruitingVaginal Microbiome | Graft Versus Host Reaction
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCesarean Section | Microbiome | Vaginal Seeding | NoseUnited States
-
Copenhagen University Hospital, HvidovreCompletedTransplantation | Vaginal Dysbiosis | Vaginal MicrobiomeDenmark
-
Medical University of ViennaUniversity of ViennaUnknown
-
National Institute of Allergy and Infectious Diseases...TerminatedVaginal Candidiasis | Microbiome | Antibiotic-Induced VVCUnited States
-
ProgenaBiomeRecruitingGastrointestinal Microbiome | Gut MicrobiomeUnited States
-
University of California, DavisCompletedGut Microbiome | Skin Microbiome | Gut Lipidome | Skin Lipidome | Blood LipidomeUnited States
Clinical Trials on OMNi-BiOTiC® FLORA plus+
-
Medical University of GrazActive, not recruiting
-
Medical University of GrazCBmed Ges.m.b.H.Active, not recruiting
-
Medical University of GrazCompletedPatients on Long-term Proton Pump Inhibitor TherapyAustria
-
Sight Sciences, Inc.TerminatedGlaucoma, Open-AngleUnited States
-
University Hospital RijekaInstitute AllergoSanRecruitingObesity | IBS - Irritable Bowel SyndromeCroatia
-
Sight Sciences, Inc.Completed
-
University MariborCompletedAcute Upper Respiratory Tract InfectionSlovenia
-
Sight Sciences, Inc.TerminatedGlaucoma, Open-AngleUnited States
-
Sight Sciences, Inc.TerminatedGlaucoma, Open-AngleGermany, Spain, United Kingdom
-
Marin GolčićUnknownColorectal Cancer MetastaticCroatia